Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney.

Daniel StehleMin Ze XuTibor SchomberMichael G HahnFrank SchwedaSusanne FeilJan R KraehlingFrank EitnerAndreas PatzakPeter Sandner Robert FeilAgnès Bénardeau

Published in: British journal of pharmacology (2021)

sGC activators increase glomerular cGMP, dilate glomerular arterioles and improve RBF under disease-relevant oxidative stress conditions. Therefore, sGC activators represent a promising class of drugs for chronic kidney disease treatment.

Keyphrases

blood flow
chronic kidney disease
diabetic nephropathy
oxidative stress
nitric oxide
high glucose
end stage renal disease
dna damage
endothelial cells
combination therapy
signaling pathway
drug induced